In the present study, we asked if a similar dependency exists in Her2+ breast cancer cells within the context of acquired resistance to Her2 inhibition, as this is the most likely clinical context where ERAD-targeted therapy might be considered in this group of patients. The gene discussed is ERBB2; the disease is breast carcinoma.